99.75
Biontech Se Adr stock is traded at $99.75, with a volume of 661.09K.
It is up +1.51% in the last 24 hours and down -10.04% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$98.27
Open:
$97.98
24h Volume:
661.09K
Relative Volume:
0.78
Market Cap:
$23.98B
Revenue:
$3.13B
Net Income/Loss:
$-381.72M
P/E Ratio:
-62.18
EPS:
-1.6042
Net Cash Flow:
$-2.15B
1W Performance:
+1.63%
1M Performance:
-10.04%
6M Performance:
-0.88%
1Y Performance:
-15.80%
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BNTX
Biontech Se Adr
|
99.75 | 23.62B | 3.13B | -381.72M | -2.15B | -1.6042 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
May-29-25 | Initiated | Goldman | Neutral |
Mar-13-25 | Initiated | Citigroup | Buy |
Jan-10-25 | Initiated | Truist | Buy |
Dec-11-24 | Initiated | Wells Fargo | Overweight |
Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
Nov-19-24 | Initiated | Berenberg | Buy |
Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
May-14-24 | Initiated | Evercore ISI | In-line |
Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
Jan-05-24 | Initiated | Oppenheimer | Perform |
Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-17-23 | Upgrade | Redburn | Neutral → Buy |
Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
Aug-17-22 | Initiated | Cowen | Market Perform |
Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-22-21 | Initiated | Deutsche Bank | Hold |
Oct-07-21 | Initiated | Jefferies | Hold |
Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
May-18-21 | Initiated | Goldman | Neutral |
May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-03-20 | Resumed | Berenberg | Buy |
Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-22-20 | Downgrade | UBS | Buy → Neutral |
Nov-05-19 | Initiated | Wolfe Research | Outperform |
Nov-04-19 | Initiated | Berenberg | Buy |
Nov-04-19 | Initiated | BofA/Merrill | Buy |
Nov-04-19 | Initiated | Canaccord Genuity | Buy |
Nov-04-19 | Initiated | JP Morgan | Overweight |
Nov-04-19 | Initiated | SVB Leerink | Outperform |
Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
37,500 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Swedbank AB - MarketBeat
Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat
Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Weekly Market Update: Stocks Gain 1.25%, Led by Technology and Communication Services - Morningstar
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Benzinga
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Ariva
BioNTech’s New PDAC Study: A Potential Game-Changer in Cancer Treatment? - MSN
BioNTech (NASDAQ:BNTX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Fred Alger Management LLC Sells 403,447 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Millennium Management LLC Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):